Evotec SE Reports Strategic Progress and Revenue Growth Amid Challenges

Evotec SE has announced its financial results for the first nine months of 2024, maintaining its revenue and EBITDA targets despite challenging market conditions. Just - Evotec Biologics saw significant growth due to collaborations with companies like Sandoz, Bristol Myers Squibb, and Pfizer. The revenue for Just - Evotec Biologics rose by 74%, contributing significantly to the company's overall performance.

The company is focused on the "Priority Reset" initiative, expecting to improve EBITDA by over €40 million. New partnerships, including an extension with Novo Nordisk, aim to boost its therapeutic solutions. Despite a 1% decline in group revenues, Evotec's biologics operations have shown impressive resilience and expansion. The opening of the J.POD facility in France marks a key milestone, improving the firm's position in biologics manufacturing.

Looking ahead, Evotec forecasts group revenues between €790 and €820 million for 2024, with R&D expenditures set to decrease.